Just over 50 years ago, President Richard M. Nixon signed into law the National Cancer Act of 1971, which established the National Cancer Institute. Cancer had become the second leading (after heart disease) cause of death in the US in 1970. The National Cancer Institute (NCI) from its establishment had broad powers, including the creation […]
26 Comments Read MoreArticles
Cancer 2023: What’s Happening in the Combat Zone?
Alex Green “Goes All-In” on Microcap — Says This Is His “#1 Stock for 2023”
March 2023 Miscellany
Osteoporosis Update (Part Two)
Relevant Updates – December 2022
Doc Gumshoe closes out 2022 with updates on Alzheimer's Disease, Flu Vaccines and more...
18 Comments Read MoreStansberry Venture’s “Major Announcement” — What are the Three Companies facing a Wave of Money?
New ads pitch a special report called "Three Ways to Make Triple-Digit Gains on Flash-Radioimmunotherapy," and we've got the Thinkolator results ... plus, a note about the also-teased "Incredible Weight-Loss Drug"
22 Comments Read MoreCOVID-19: What Now?
Most of this Doc Gumshoe posting was ready to go a couple of days before Thanksgiving. But then, you know what happened: the new variant (now named Omicron) surfaced in South Africa. So I finished up another Doc Gumshoe epistle that I had been working on and quickly got it to Travis so I could […]
70 Comments Read MoreWhat’s Basenese’s “PGB” Stock? Thinkolator Answers Coming Your Way…
New ad for Micro-Cap Advantage hints at huge gains ahead if you buy before November 14 -- what's the story?
12 Comments Read MoreMay Miscellany – Some Covid-19, Some Otherwise
Doc Gumshoe looks at Herd Immunity, Vaccines and Treatments... plus some updates on Alzheimer's Disease, Dementia and more...
33 Comments Read MoreWhat’s New on the CRISPR Front?
Aside from the tiny minority of people who can actually say what each of those initials stand for, we can divide the populace into two groups – those who specifically know that CRISPR is a tool used in gene editing and those who know (or figure) that it’s a highly promising but exceedingly complex technique […]
27 Comments Read MoreCOVID 19: What Are Prospects for the Duration?
Doc Gumshoe on Arizona, Sweden, Herd Immunity and the Progress of Vaccine Programs
56 Comments Read MoreAnother Look at the Current Migraine Scene
Thinking about COVID-19 almost gives me a migraine, or at least a heavy and achy sensation in my noggin – perhaps not an actual migraine, thankfully, but threatening and unpleasant all the same. Happily, thinking about migraines will not give me COVID-19. But migraines are by no means a topic of no consequence, […]
13 Comments Read More58,300% Sales Surge for “Super Vaccine” Company?
What's being touted by Money Morning in ads for Michael Robinson's new Bio-Technology Profit Alliance?
42 Comments Read MoreMichael Robinson’s “ONLY Solution” for COVID-19 (with June 30 Results Expected!)
Ads for Nexus-9 tease that "Over 70 firms are racing to produce the most critical vaccine of all time. But only one of them can give you a shot at making 3,000%." So... who is it?
71 Comments Read MoreWhat’s that “First and Best Drugs” Alzheimer’s Stock for 300% gains?
What's teased as the latest Alzheimer's Disease recommendation from Dave Lashmet for Stansberry's Investment Advisory?
13 Comments Read MoreWhat’s Bonner’s “FDA Fast Tracks $6.8 Billion Miracle Antibiotic” pitch about?
Checking into Jeff Brown's "July 1st Approval" teaser pitch -- he says that " I believe this tiny company is sitting on the biggest medical breakthrough in over three decades. Possibly since the discovery of penicillin in 1928."
59 Comments Read MoreA Look at the Promise of Gene Editing
Alzheimer’s Disease: 2019 Refresher and Updates
Combating Cancer: The Current Battle Plan
Cancer: The Lay of the Land in 2018
Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
34 Comments Read More“Rising Healthcare Demand Enables 100+ Year Dividend-Paying Pharma Giant to Enter Best Dividend Stocks List”
Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]
8 Comments Read MoreWhat’s New this Summer?
Oncotutorial
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]
4,732 Comments Read MoreFriday File: Debt Ceiling, Gold, Fairfax and Ligand
Hello, merry Gumshoe-ers! I’m going to be on the road next week to attend two conferences, the Grant’s Interest Rate Observer conference in New York mid-week, and the MIT Sloan Conference on Friday — so I’ll be sharing some notes with you with my thoughts on what I hear at those confabs, with fingers crossed […]
13 Comments Read MoreSkousen’s “must have” cancer killer stock… and it’s “one of the world’s oldest, publicly traded companies”
We're teased that "Dr. Skousen just put it at the top of his Recommended List" -- what is it?
10 Comments Read MoreHow Concerned Do We Need to Be About Drug Side Effects?
Two Flubs and a Big Question Mark
What’s the “Miracle on Mount Ararat” Drug?
Stansberry’s “Magic Stock of 2016” from the “Best Portfolio Strategy We’ve Ever Tested”
What's being hinted at as the "only magic stock today" found by the Stansberry Data service?
32 Comments Read MoreAlzheimer’s Wrap-Up
Abiding Ambiguity: Achaogen and Arrowhead
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He choses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Enjoy!] In his smoky baritone, singer Stuart Staples of British midlands musical act Tindersticks is bemoaning how he suspects the woman he […]
151 Comments Read MoreGumshoe BioDimSum II: Corralling the “A” Biotechs Plus a New Long Selection
[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]
1,002 Comments Read MoreCancer Care: Current Directions
The 2015 Stock Gumshoe Biotechnology Awards Show!
Biotech Dim Sum: ARTH, CLDN, ESPR, BLRX, GILD and a New Baby Biotech for 2015
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. His previous columns can be found here. Enjoy!] Every New Year, a friend and I flew to Boston. She’d gone to medical school […]
544 Comments Read MoreDoc Gumshoe’s News: Some Good, Some Not So Good
[ed note: Michael Jorrin, who we like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who writes non-investment articles about medicine and health topics for us once or twice a month. As with all of our guest contributors and columnists, he chooses his own topics and his words are his alone] […]
23 Comments Read MoreNeed to Know: Special Update on Achaogen
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions.] If you get infected with CRE in your blood, your lungs, your urine, or your biliary system, what is your chance of […]
Leave a comment Read MoreEbola: To Parse, Perchance to Parlay
Biosimilars: What Are They, and Why On Earth Should We Care?
The Gain from Pain Mainly Explained: Fire Walk with Me
Where is the Management of Type 2 Diabetes Heading?
[ed note: Michael Jorrin, a medical writer who we have dubbed “Doc Gumshoe” (he’s not a doctor), shares his thoughts with us once or twice a month — what follows is his latest missive, the words and opinions below are his alone.] I didn’t plan it this way, but the timing of this Doc Gumshoe […]
64 Comments Read MoreHepatitis with a C
Hepatitis with a C: Right Now Someone You Know Has It (and Doesn’t Know)
Just For the Record
Can you really “Create Extra Paychecks Month After Month Thanks to the ‘MCR Plan?'” (Leeb)
Figuring out the "Income Stacking" picks teased by Stephen Leeb's Complete Investor
5 Comments Read More“Part D Compensation — 550% gains, nine years of monthly checks”
This one comes in from Stansberry and Associates, as an ad for Porter Stansberry’s Investment Advisory — if you subscribe, they’ll send you the special report: “Part D Compensation”— Monthly Checks for the Next 9 Years. Now, Stansberry and his folks love to come up with new terms and phrases to describe the investment strategies […]
1 Comment Read MoreWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
#Biotech Best turnaround M&A$ARQL 20X $MRK BO in 2yr$ARRY $2s Multiple setbacks ➡️ 20X $PFE BO in 3yr$ECYT...
Good work! Elfenbein appears to have missed the first cycle move on CTST, but might be close on the entry for the next o...
Merck (MRK) Keytruda/Chemo combo getting a lot of attention at ESMO. https://endpts.com/esmo-roundup-immune-design-roll...
$MRK - breakingMerck snaps up a German immuno-oncology upstart in a $603M bolt-on dealMunich-based Rigontec is d...
$ESPR (of high relevance) $MRK $CETPMerck hits a bloop single in an epic PhIII CETP cardio contest. Now what? (Endpo...
$ESPR $MRK #CETP #CVOTMerck Provides Update on REVEAL Outcomes Study of AnacetrapibBusiness Wire Business WireJu...
Should bode well for $NTRPLong $NTRPMerck $MRK announced late Tuesday that it is shuttering its EPOCH trial for ...
Dear KSS. Since Merck ($MRK) settled with Bristol Meyer ($BMY) Friday regarding anti-PD-1 antibodies has this set a prec...
$INCY $MRK:Shares of Incyte ($INCY) soared Monday on the heels of news that the company and Merck ($MRK) will condu...
Merck (MRK) with good news.http://www.marketwatch.com/story/merck-beats-profit-expectations-bumps-up-full-year-guida...
I will also clarify that the Merck/ECYT deal was with Merck (MRK), not Merck KGaA (EMD Serono) so they were different co...
$ESPR Red Acre Investments · @redacre http://www.twitlonger.com/show/n_1snl7e3 13th Oct 2015 from TwitLonger Thesis...
Although I have never understood why Merck $MRK received it, the FDA has yanked Breakthrough Therapy Designation for its...
RE:GILD – good news from Barron’s. Long GILD. RBC’s Michael Yee and team think AbbVie’s (ABBV) update on its he...
True, there are always expensive companies, but that's 20X estimated earnings for 2017, 30 months into the future. BMY ...
Just saw this - another entry in the HCV parade: Jackpot for Idenix Shareholders -- Market TalkMonday 06/09/2014 07:41 ...
om and others. Here is the WSJ article. Sorry for the delay. It was sunny in Seattle and you gotta take advantage ...
Companies those working on RNA therapeutics, like Fierce Biotech broke the news that the Swiss giant, Novartis (NVS) was...
In regards to OPK;Opko Health (OPK), is expecting to announce top-line results from its Phase III trial for rola...